Related Experiment Video

Updated: Jun 12, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

[Proteasome inhibitor]

Masahiro Yamamura1, Toshihiro Hirai, Yoshiyuki Yamaguchi

  • 1Department of Clinical Oncology, Kawasaki Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 12, 2010
PubMed

Insights

Proteasome inhibition, targeting the ubiquitin-proteasome pathway, shows promise for treating solid tumors. Bortezomib, a proteasome inhibitor, demonstrates cytotoxic effects on various cancer cells in vitro.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • The ubiquitin-proteasome pathway is crucial for regulating cellular proteins involved in critical processes like cell cycle control, transcription, apoptosis, and tumor growth.
  • Dysregulation of this pathway is implicated in various cancers, making it a target for therapeutic intervention.

Purpose of the Study:

  • To discuss the utility of proteasome inhibitors in cancer therapy.
  • To review preclinical and clinical studies of proteasome inhibitors, both as monotherapy and in combination with conventional chemotherapy.

Main Methods:

  • Review of existing preclinical and clinical studies on proteasome inhibitors.
  • In vitro experiments evaluating the cytotoxic effects of bortezomib on diverse cancer cell lines.

Main Results:

  • Proteasome inhibition is identified as a novel therapeutic strategy for solid tumors.
  • Bortezomib, the first proteasome inhibitor in clinical trials, exhibits in vitro cytotoxicity against breast, colorectal, ovarian, pancreatic, prostate, lung, and oral cancer cells.

Conclusions:

  • Proteasome inhibitors represent a promising approach for cancer treatment.
  • Further investigation into bortezomib and other proteasome inhibitors, alone or in combination, is warranted for solid tumor therapy.

More Related Videos

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron (dgn)-destabilized Green Fluorescent Protein (GFP)-based Reporter Protein10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron (dgn)-destabilized Green Fluorescent Protein (GFP)-based Reporter Protein

Published on: November 10, 2012

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...